Navigation Links
Vanda Pharmaceuticals Appoints Chief Commercial Officer
Date:10/24/2011

ROCKVILLE, Md., Oct. 24, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it has named Bob Repella as Senior Vice President, Chief Commercial Officer of the company.

Mr. Repella has more than 25 years of experience in the biotech/pharmaceutical industry, including senior-level leadership roles in global marketing, sales, new product development and commercial operations.  

"We are very pleased to welcome Bob to the Vanda team," said Mihael Polymeropoulos, M.D., President and CEO of Vanda.  "His depth of industry experience and proven track record across a wide spectrum of therapeutic areas are expected to be pivotal to the commercial success of Vanda's product pipeline."

Prior to joining Vanda, Mr. Repella was Senior Vice President of Pharmaceutical Operations for the America's Region at Cephalon, Inc.  In this position, he was responsible for all commercial operations in North and South America, including brand marketing, sales, managed markets and new product planning.  This included oversight of all therapeutic categories (CNS, Oncology and Pain), partnership agreements and the Mepha generics division.      

Before joining Cephalon, Mr. Repella was Executive Vice President and General Manager of the Biopharma Business Unit for Wyeth Pharmaceuticals.  In this position, he was responsible for the global portfolio of products across Wyeth's immunology, oncology and hemophilia franchises. During his 16 years at Wyeth, Mr. Repella served in various roles in both marketing and sales, including Executive Vice President Pharmaceutical Sales, Marketing and Operations; Senior Vice President, Pharmaceutical Sales; and Vice President, Global Business Manager, Enbrel®.  

Earlier in his career, Mr. Repella held positions with Johnson & Johnson's McNeil Pharmaceutical Division, Merck & Co., Inc. and Eli Lilly & Co.  Mr. Repella received his Bachelors Degree in Pharmacy from Rutgers University and a Masters in Business Administration from Temple University.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders. For more on Vanda, please visit http://www.vandapharma.com/.

Media Contact:
Cristina Murphy
+1-240-599-4500
cristina.murphy@vandapharma.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a ... commercialization of innovative therapies for the treatment of ... Agency (EMA) has notified the company that the ... Application (MAA) has passed validation, and that the ... MAA for ARX-04 (known as DSUVIA™ in the ...
(Date:3/28/2017)... 2017 The global surgical ... value of USD 4.5 billion by 2025, according to ... closure of injured tissues post operation is a major ... occur in 3% to 15% of cases and are ... one third of postoperative deaths in patients. Surgical sealants ...
(Date:3/28/2017)... 28, 2017 Elysium Health joins ... Cambridge academic scientists ... The Milner Therapeutics Institute today announces Elysium Health as ... committed significant investment for collaborative projects with academic researchers in ... This is the first major research investment outside the U.S. ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 28, 2017 , ... The Executives, Staff & Clients of MGE: Management Experts ... for Tots Literacy Campaign at their Semi-Annual Graduation and Fundraiser Event at MGE’s St. ... ranks at number 14 internationally in literacy. Statistically, a direct relation can be a ...
(Date:3/28/2017)... ... 2017 , ... Public relations pros work hard to earn placements and ... While many results are clear, much of PR is hard to quantify. Goal-setting and ... to measurement, firms should always take an all-inclusive approach that takes both traditional and ...
(Date:3/28/2017)... ... March 28, 2017 , ... Thank you to all who ... 8-10. , This event was exclusive to providers and offered an opportunity to ... took place at the Manchester Grand Hyatt where attendees gathered for a lively discussion ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... patients for clear braces. People who want straight teeth without the extensive time ... in Clearwater, FL, without acquiring a referral. A custom-designed series of virtually ...
(Date:3/27/2017)... ... March 27, 2017 , ... This is the ... popHealth Community in 2014. It is the culmination of collaborative efforts by ... Project Group. OSEHRA Organizational Member Zato Health co-funded the ONC certification and provided ...
Breaking Medicine News(10 mins):